Pulmonx (LUNG) Common Equity (2019 - 2025)

Pulmonx (LUNG) has 7 years of Common Equity data on file, last reported at $54.1 million in Q4 2025.

• Quarterly Common Equity fell 36.93% year-over-year to $54.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $54.1 million (down 36.93% YoY) and the FY2025 annual result came in at $54.1 million, down 36.93% from the prior year.
• Common Equity fell to $54.1 million in Q4 2025 per LUNG's latest filing, from $60.0 million in the prior quarter.
• Across five years, Common Equity topped out at $216.1 million in Q1 2021 and bottomed at $54.1 million in Q4 2025.
• The 5-year median for Common Equity is $129.8 million (2023), against an average of $133.4 million.
• The widest annual swing landed in 2021, when Common Equity soared 211.39%; it then tumbled 36.93% in 2025.
• Tracing LUNG's Common Equity over 5 years: stood at $193.2 million in 2021, then fell by 20.3% to $154.0 million in 2022, then decreased by 23.18% to $118.3 million in 2023, then retreated by 27.47% to $85.8 million in 2024, then sank by 36.93% to $54.1 million in 2025.
• Per Business Quant, the three latest LUNG Common Equity figures stand at $54.1 million (Q4 2025), $60.0 million (Q3 2025), and $69.1 million (Q2 2025).

Peer Comparison